Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUDIOWOLF: Sodium Valproate in Wolfram Syndrome
NCT04940572Phase 2Recruiting
- Sponsor
- Centre d'Etude des Cellules Souches
- Start
- Nov 2021
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of valproic acid in Wolfram syndrome, sponsored by Centre d'Etude des Cellules Souches. Primary endpoint: Preservation of auditory function at 156 weeks. Started Nov 2021; status: recruiting.
02
Drugs
valproic acid
03
Conditions
Wolfram syndrome
Beyond the preview
Go deeper on NCT04940572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04940572.